drugset / Trial / NCT01052103
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
Timeline
- Start
- 2010-01
- Primary completion
- 2012-06
- Completion
- 2012-06
Outcome
Missed primary endpoint
registry analysis (unspecified test); LY2140023 + SOC vs Placebo + SOC; p = 0.732; LS Mean Differences 1.0; Type 3 Tests; note: One-sided p-value. NCT01052103 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2140023 | Unknown | 40 mg | Oral |
| Background | Aripiprazole | Other / unclassified | — | — |
| Background | Olanzapine | Small molecule | — | — |
| Background | Quetiapine | Small molecule | — | — |
| Background | Risperidone | Other / unclassified | — | — |